Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Potoczak, R E"'
Autor:
Willardsen, J. A., Dudley, D. A., Cody, W. L., Chi, L., McClanahan, T. B., Mertz, T. E., Potoczak, R. E., Narasimhan, L. S., Holland, D. R., Rapundalo, S. T., Edmunds, J. J.
Publikováno v:
Journal of Medicinal Chemistry; July 2004, Vol. 47 Issue: 16 p4089-4099, 11p
Publikováno v:
The Journal of Pharmacology and Experimental Therapeutics; July 1980, Vol. 214 Issue: 1 p50-57, 8p
Autor:
Ignasiak, D. P., McClanahan, T. B., Saganek, L. J., Potoczak, R. E., Hallak, H., Gallagher, K. P.
Publikováno v:
European Journal of Pharmacology; 1997, Vol. 321 Issue: 3 p295-300, 6p
Autor:
Albassam MA; Pfizer Global Research and Development, Ann Arbor Michigan, 48105, USA. mudher.albassam@pfizer.com, Metz AL, Potoczak RE, Gallagher KP, Haleen S, Hallak H, McGuire EJ
Publikováno v:
Toxicologic pathology [Toxicol Pathol] 2001 May-Jun; Vol. 29 (3), pp. 277-84.
Autor:
Saganek LJ; Vascular and Cardiac Diseases Section, Parke-Davis Pharmaceutical, Ann Arbor, Michigan 48105, USA. saganel@aa.wl.com, Ignasiak DP, Batley BL, Potoczak RE, Dodd G, Gallagher KP
Publikováno v:
Basic research in cardiology [Basic Res Cardiol] 1997 Oct; Vol. 92 (5), pp. 331-8.
Reduction of canine myocardial infarct size by CI-959, an inhibitor of inflammatory cell activation.
Autor:
Burke SE; Department of Pharmacology, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Michigan., Wright CD, Potoczak RE, Boucher DM, Dodd GD, Taylor DG Jr, Kaplan HR
Publikováno v:
Journal of cardiovascular pharmacology [J Cardiovasc Pharmacol] 1992 Oct; Vol. 20 (4), pp. 619-29.